Joseph Skitzki, MD, Director of Melanoma and Cutaneous Oncology Surgery at Cleveland Clinic, joins the Cancer Advances podcast to discuss how neoadjuvant immunotherapy is transforming melanoma treatment. Listen as Dr. Skitzki explains how this approach is improving survival and reducing the need for extensive surgery.
All content for Cleveland Clinic Cancer Advances is the property of Cleveland Clinic Taussig Cancer Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Joseph Skitzki, MD, Director of Melanoma and Cutaneous Oncology Surgery at Cleveland Clinic, joins the Cancer Advances podcast to discuss how neoadjuvant immunotherapy is transforming melanoma treatment. Listen as Dr. Skitzki explains how this approach is improving survival and reducing the need for extensive surgery.
Breathing New Life Into Cancer Treatment: Inhaled KB707
Cleveland Clinic Cancer Advances
17 minutes
2 months ago
Breathing New Life Into Cancer Treatment: Inhaled KB707
Wen Wee Ma, MBBS, Enterprise Vice Chair for Research and Director of the Novel Cancer Therapeutics Center, joins the Cancer Advances Podcast to discuss a phase 1 trial of KB707 presented at ASCO 2025. This innovative therapy delivers IL-2 and IL-12 directly to the lungs through inhalation, aiming to minimize side effects and improve outcomes for patients with lung tumors. Dr. Ma shares early trial results and what they could mean for the future of cancer treatment.
Cleveland Clinic Cancer Advances
Joseph Skitzki, MD, Director of Melanoma and Cutaneous Oncology Surgery at Cleveland Clinic, joins the Cancer Advances podcast to discuss how neoadjuvant immunotherapy is transforming melanoma treatment. Listen as Dr. Skitzki explains how this approach is improving survival and reducing the need for extensive surgery.
